Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 32, Issue 9, Pages 507-513Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2011.05.001
Keywords
-
Categories
Funding
- Johnson Johnson
- Lundbeck
- Pfizer
- GSK
- Puretech Ventures
- Merck
- Takeda
- Dainippon Sumitomo
Ask authors/readers for more resources
Substantial evidence suggests that psychosis in schizophrenia is associated with dysregulation of subcortical dopamine system function. Here we examine evidence that this dysregulation is secondary to hyperactivity within hippocampal subfields. Enhanced hippocampal activity has been reported in preclinical models and in schizophrenia patients. Moreover, this hippocampal hyperactivity is correlated with enhanced dopamine neuron activity and positive symptoms, respectively. Thus, restoration of hippocampal function could provide a more effective therapeutic approach than current therapeutics based on blockade of dopamine 02 receptors. Indeed, initial studies demonstrate that allosteric modulation of the alpha 5GABA(A) receptor can decrease aberrant dopamine signaling and associated behaviors in a verified rodent model of psychosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available